Gilead’s rep takes an­oth­er pun­ish­ing blow as a bad, no good, aw­ful year just got worse

Round two in the heavy­weight fight over con­trol of bil­lions of dol­lars in he­pati­tis C drug mon­ey goes to Mer­ck af­ter a ju­ry lev­eled a knock­out, $2.54 bil­lion punch against Gilead for vi­o­lat­ing its drug patents.

The record patent judg­ment cov­ers a 10% roy­al­ty pay­ment on Gilead’s block­buster sales for So­val­di and Har­voni, with the ju­ry adding in­sult to in­jury by up­hold­ing Mer­ck’s patent claims, which orig­i­nat­ed from its $3.9 bil­lion buy­out of Idenix in 2014.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.